Skip to main content

CORRECTION article

Front. Pharmacol., 01 March 2023
Sec. Cardiovascular and Smooth Muscle Pharmacology
Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1169734

Corrigendum: Artemisinin relieves myocardial ischemia-reperfusion injury via modulating miR-29b-3p and hemicentin 1

This article is a correction to:

  1. Artemisinin relieves myocardial ischemia-reperfusion injury via modulating miR-29b-3p and hemicentin 1

    1. Read original article
Junyu HanJunyu Han1Ziguan ZhangZiguan Zhang1Zhonghe ZhangZhonghe Zhang1Shuyu Yang Shuyu Yang2*
  • 1Department of Cardiology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China
  • 2Xiamen Diabetes Institute, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China

A Corrigendum on
Artemisinin relieves myocardial ischemia-reperfusion injury via modulating miR-29b-3p and hemicentin 1

by Han J, Zhang Z, Zhang Z and Yang S (2022). Front. Pharmacol. 13:918966. doi: 10.3389/fphar.2022.918966

In the published article, there was an error in Figure 6 as published. The corrected Figure 6 and its caption appear below.

FIGURE 6
www.frontiersin.org

FIGURE 6. ARS suppresses myocardial I/R injury through regulating miR-29b-3p/HMCN1 in vivo.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: myocardial ischemia-reperfusion, artemisinin, high throughput sequencing, miR-29b-3p, hemicentin 1, oxidative stress

Citation: Han J, Zhang Z, Zhang Z and Yang S (2023) Corrigendum: Artemisinin relieves myocardial ischemia-reperfusion injury via modulating miR-29b-3p and hemicentin 1. Front. Pharmacol. 14:1169734. doi: 10.3389/fphar.2023.1169734

Received: 20 February 2023; Accepted: 21 February 2023;
Published: 01 March 2023.

Edited and reviewed by:

Silvia Nistri, University of Florence, Italy

Copyright © 2023 Han, Zhang, Zhang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Shuyu Yang, ysyxmu@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.